Fiche publication
Date publication
mai 2026
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher
Tous les auteurs :
Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Zampino MG, Casanova N, Guimbaud R, Lievre A, Maurel J, Zhang P, Munteanu MC, Jones M, de la Fouchardiere C, Takashima A, Fakih M, Spano J
Lien Pubmed
Résumé
In the primary analysis of the POD1UM-303/InterAACT 2 trial, median progression-free survival (PFS) was significantly longer with retifanlimab plus carboplatin-paclitaxel than with placebo plus carboplatin-paclitaxel in adult, systemic treatment-naïve patients with advanced/metastatic squamous cell carcinoma of the anal canal (SCAC). Here, the final overall survival (OS) data from PODIUM-303/InterAACT 2, along with subgroup and exploratory analyses, are presented.
Mots clés
immunotherapy, overall survival, progression-free survival, retifanlimab, squamous cell anal cancer
Référence
Ann Oncol. 2026 05 5;:
